Each tablet contains SitagIiptin Phosphate 50 mg / 100 mg
Monotherapy and combination therapy
Sitafer is Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Upper respiratory tract Infection, nasopharyngitis and headache
Vildagliptin 50mg
Vildagliptin is indicated in the treatment of type 2 diabetes mellitus in adults:
As monotherapy
In patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.
As dual oral therapy in combination with Metformin, in patients with insufficient glycemic control despite maximal tolerated dose of monotherapy with metformin.
A sulphonylurea, in patients with insufficient glycemic control despite maximal tolerated dose of a sulphonylurea and for whom metformin is inappropriate due to contraindications or intolerance.
A thiazolidinedione, in patients with insufficient glycemic control and for whom the use of a thiazolidinedione is appropriate.
As triple oral therapy in combination with
A sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycemic control.
Vildagliptin is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycemic control.
Common: Dizziness
Uncommon: Headache, constipation, swollen hands, ankle or feet edema, joint pain, low blood glucose.
Rare: Angioedema, Hepatitis
Very rare: Sore throat, runny nose, fever
